Residents and Fellows Research in Progress
Sunday, October 13, 2024
12:45 PM–02:15 PM
Abstract
Introduction:
Limited data exists regarding the safety and efficacy of concomitant low-dose aspirin for primary prevention of atherosclerotic cardiovascular disease (ASCVD) and direct oral anticoagulant (DOAC) for thromboembolism prevention in atrial fibrillation (AF). This study will assess the
safety of aspirin in patients with AF without ASCVD receiving DOACs.
Research Question or Hypothesis: What is the incidence of bleeding, according to the criteria of the International Society on Thrombosis and Haemostasis (ISTH), in patients initiated on a DOAC for thromboembolism prevention in AF plus low-dose aspirin for primary prevention of ASCVD versus DOAC monotherapy?
Study Design: Retrospective cohort study of patients admitted with AF from January 1st, 2021, to June 1st, 2024.
Methods: This retrospective cohort study assessed the incidence of bleeding in patients with AF receiving dual therapy with a DOAC (apixaban or rivaroxaban) for thromboembolism prevention in AF and low-dose aspirin for primary prevention of ASCVD, compared to patients receiving a DOAC alone. Patients were excluded if they had a prior ASCVD event, were taking warfarin or non-aspirin antiplatelets, were on a DOAC for reason other than AF, had a mechanical or bioprosthetic heart valve, moderate to severe mitral stenosis, chronic kidney disease stage 4-5, or end-stage renal disease. The primary outcome was incidence of ISTH major bleeding, per 100 patient-years. Secondary outcomes included incidence of ISTH clinically relevant non-major bleeding, per 100 patient-years, and hospitalization for an ischemic event, including acute coronary syndrome, acute ischemic stroke or transient ischemic attack, and peripheral artery disease.
Results: To be presented.
Conclusion: To be presented.
Presenting Author
Storee Yzaguirre PharmDWest Virginia University Medicine
Authors
Lauren Kunkel PharmD
WVU Medicine
Jordan Lacoste PharmD
WVU Medicine
Matthew Rockhold PharmD
WVU Medicine
Thomas Szymanski PharmD
WVU Medicine